{
    "clinical_study": {
        "@rank": "48779", 
        "arm_group": {
            "arm_group_label": "EPZ-5676", 
            "arm_group_type": "Experimental", 
            "description": "EPZ-5676 Dose escalation and expansion cohorts"
        }, 
        "brief_summary": {
            "textblock": "A subset of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia\n      (ALL) harbor rearrangements of the MLL gene, which are detected either by cytogenetic or\n      fluorescent in situ hybridization evaluation at the time of diagnosis. A protein called\n      DOT1L plays an important role in the malignant process in these leukemias. EPZ-5676 is a\n      molecule that blocks the activity of DOT1L, and is therefore being evaluated in the\n      treatment of patients with MLL-rearranged leukemias."
        }, 
        "brief_title": "Dose Escalation Study of EPZ-5676 in Pediatric Patients With Leukemias Bearing a Rearrangement of the MLL Gene", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Leukemia", 
            "Acute Myeloid Leukemia", 
            "Acute Lymphocytic Leukemia", 
            "Acute Leukemias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Acute Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1b study of EPZ-5676 in pediatric patients. The study will have two phases.\n      The first phase will assess escalating doses of EPZ-5676 in order to determine the maximally\n      tolerated dose (MTD) or recommended phase 2 dose (RP2D) of EPZ-5676 as a 28-day continuous\n      IV infusion. Once the MTD and/or RP2D is established, a second phase of the study will\n      further evaluate the safety of EPZ-5676 and assess the anti-leukemia activity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: 3 months to <18 years of age.\n\n          2. Diagnosis: Patients must have documented relapsed/refractory ALL, AML, or acute\n             leukemia of ambiguous lineage and meet the following criteria:\n\n               -  Patients must have at least received an appropriate induction therapy regimen.\n                  Patients with persistent leukemia after induction therapy, or with recurrence of\n                  leukemia at any time during the course of treatment (including allogeneic HSCT)\n                  are eligible;\n\n               -  Patients must have > 10% leukemic blasts (or blast equivalents) in the bone\n                  marrow;\n\n               -  Patients must have rearrangement involving the MLL gene, including reciprocal\n                  chromosomal translocations involving 11q23 by FISH or cytogenetic analysis, or\n                  partial tandem duplication (PTD) of MLL by polymerase chain reaction (PCR) or\n                  next-generation sequencing (NGS).\n\n          3. Therapeutic Options:  Patients must be ineligible or inappropriate for other\n             treatment regimens known to have curative potential.\n\n          4. Performance Level:  Karnofsky > 50% for pts > 12 years; Lansky > 50% for pts < 12\n             years of age.\n\n          5. Prior Therapy: Patients must have fully recovered from the acute toxic effects of all\n             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.\n\n             Myelosuppressive Chemotherapy:\n\n               -  14 days must have elapsed since the completion of cytotoxic therapy\n\n               -  Patients may receive hydroxyurea, low-dose cytarabine and/or glucocorticoids to\n                  control peripheral blood leukemic cell counts at study entry\n\n               -  At least 7 days since the completion of therapy with hematopoietic growth\n                  factors\n\n               -  At least 7 days since the completion of therapy with a biologic agent\n\n               -  At least 60 days from prior total body irradiation (TBI)\n\n               -  At least 60 days must have elapsed from hematopoietic stem cell transplantation\n                  (HSCT)\n\n          6. Renal and Hepatic Function:  Patient must have adequate renal and hepatic functions\n             as indicated by the following laboratory values:\n\n               -  Patient must have a calculated creatinine clearance or radioisotope GFR >\n                  60mL/min/1.73m2 or a normal serum creatinine based on age/gender\n\n               -  Total bilirubin < 1.5 x UNL for age or normal conjugated bilirubin\n\n               -  ALT and AST < 3 x ULN (unless attributed to leukemic involvement)\n\n          7. Cardiac Function:  Patient must have a shortening fraction (SF) of  > 27% or an\n             ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.\n\n        Exclusion Criteria:\n\n          1. Patients with CNS 3 disease\n\n          2. Clinically active heart disease including prolonged QTc\n\n          3. On immunosuppressive or other anti-leukemic therapy, excluding patients  receiving\n             glucocorticoids for management of circulating blast count or patients on a stable\n             dose (<20mg/m2/day prednisone or equivalent) of systemic or topical glucocorticoid\n             therapy with \u2264 Grade 1 GvHD\n\n          4. Patients with known bleeding diathesis or prothrombin time (PT) or aPTT >1.5 x ULN or\n             fibrinogen <0.5 x LLN\n\n          5. Receiving prophylactic use of hematopoietic colony stimulating factors\n\n          6. Known history of infection with human immunodeficiency virus (HIV) or chronic\n             infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV\n             positive)\n\n          7. Being actively treated for another concurrent malignancy\n\n          8. Pregnant or nursing females;\n\n          9. Male patients not willing to use a condom\n\n         10. Uncontrolled intercurrent illness including, but not limited to uncontrolled\n             infection, significant graft-versus-host-disease (GvHD) (Grade 2-4), or psychiatric\n             illness/social situations that would limit compliance with study requirements\n\n         11. Patients who are concurrently receiving strong inducers/inhibitors of CYP3A"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141828", 
            "org_study_id": "EPZ-5676-12-002"
        }, 
        "intervention": {
            "arm_group_label": "EPZ-5676", 
            "description": "28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.", 
            "intervention_name": "EPZ-5676", 
            "intervention_type": "Drug", 
            "other_name": [
                "EPZ5676", 
                "DOT1L"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Leukemia", 
            "Advanced hematologic malignancies", 
            "Epizyme", 
            "Phase 1b", 
            "MLL gene", 
            "11q23", 
            "Ambiguous lineage", 
            "ALL", 
            "AML", 
            "Acute leukemias", 
            "MLL-r"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "PGaynon@chla.usc.edu", 
                    "last_name": "Paul Gaynon, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Childrens Hospital Los Angeles"
                }, 
                "investigator": {
                    "last_name": "Paul Gaynon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Lia.Gore@ucdenver.edu", 
                    "last_name": "Lia Gore, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Children's Hospital Colorado"
                }, 
                "investigator": {
                    "last_name": "Lia Gore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "pbrown2@jhmi.edu", 
                    "last_name": "Pat Brown, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "Pat Brown, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Lewis_Silverman@dfci.harvard.edu", 
                    "last_name": "Lewis Silverman, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Lewis Silverman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "shuklan@MSKCC.ORG", 
                    "last_name": "Neal Shukla, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Neal Shukla, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "maureen.obrien@cchmc.org", 
                    "last_name": "Maureen O'Brien, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }, 
                "investigator": {
                    "last_name": "Maureen O'Brien, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene", 
        "other_outcome": {
            "measure": "To determine cerebrospinal fluid (CSF) concentrations EPZ-5676 in pediatric patients receiving EPZ-5676 by CIV infusion", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "overall_contact": {
            "email": "clinicaltrials@epizyme.com", 
            "last_name": "Blythe Thomson, MD", 
            "phone": "855-500-1011"
        }, 
        "overall_contact_backup": {
            "email": "clinicaltrials@epizyme.com", 
            "last_name": "Eric Hedrick, MD", 
            "phone": "855-500-1011"
        }, 
        "overall_official": [
            {
                "affiliation": "Memorial Sloan-Kettering Cancer Center", 
                "last_name": "Neal Shukla, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children's Hospital Colorado", 
                "last_name": "Lia Gore, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Johns Hopkins University", 
                "last_name": "Pat Brown, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dana Farber", 
                "last_name": "Lewis Silverman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children's Hospital Los Angeles", 
                "last_name": "Paul Gaynon, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children's Hospital Medical Center, Cincinnati", 
                "last_name": "Maureen O'Brien, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676 as determined by incidence of protocol-specified dose-limiting adverse events.", 
                "measure": "Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676.", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Safety and tolerability will be assessed by the incidence of adverse events in patients treated with EPZ-5676 and the evaluation of adverse events, vital signs, physical examination, 12-lead ECG, and laboratory assessments.", 
                "measure": "To assess the safety and tolerability of EPZ-5676 administered as a continuous intravenous (CIV) infusion", 
                "safety_issue": "Yes", 
                "time_frame": "18 months."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The pharmacokinetic (PK) profile will include the analysis of Cmax, AUC and steady state concentration of EPZ-5676.\nThe pharmacodynamic (PD) profile will assess the effects on histone H3K79 methylation in peripheral blood mononuclear (PBMC) and bone marrow cells.", 
            "measure": "Determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPZ-5676", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "source": "Epizyme, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Epizyme, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}